

## STANDARD TREATMENT WORKFLOW (STW)

# Atrial Fibrillation

S. K. Dwivedi<sup>1</sup>, George Joseph<sup>2</sup>, Aditya Kapoor<sup>3</sup>, G Karthikeyan<sup>4</sup>, Paul V George<sup>5</sup>, Santhosh Satheesh<sup>6</sup>, Saurabh Mehrotra<sup>7</sup>, Praveen Chandra<sup>8</sup>, Amit M Vora<sup>9</sup>, Calambur Narasimhan<sup>10</sup>, Paul V George<sup>11</sup>, Praveen Chandra<sup>12</sup>

<sup>1</sup>King George's Medical University, Lucknow;<sup>2</sup>Christian Medical College Vellore;<sup>3</sup>Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow;<sup>4</sup>All India Institute of Medical Sciences, New Delhi.;<sup>5</sup>Christian Medical College Vellore;<sup>6</sup>Jawaharlal Institute of Postgraduate Medical Education and Research, Pondyicherry;<sup>7</sup>Postgraduate Institute of Medical Education and Research, Chandigarh;<sup>8</sup>Medanta, Gurgaon;<sup>9</sup>Reliance, Mumbai.;<sup>10</sup>CARE, Hyderabad;<sup>11</sup>Christian Medical College Vellore;<sup>12</sup>Medanta, Gurgaon

### CORRESPONDING AUTHOR

Dr SK Dwivedi, King George's Medical University, Lucknow

Email: [drskdwivedi60@gmail.com](mailto:drskdwivedi60@gmail.com)

### CITATION

Dwivedi SK, Joseph G, Kapoor A, Karthikeyan G, George PV, Satheesh S, Mehrotra S, Chandra P, Vora AM, Narasimhan C, George PV, Chandra P. Atrial Fibrillation. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S203-S204. DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.102>

*This work is licensed under a Creative Commons Attribution 4.0 International License.*

*©The Author(s). 2024 Open Access*

### DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.


October 2024



## Standard Treatment Workflow (STW) for the Management of

# ATRIAL FIBRILLATION

ICD-10-I48.91



October 2018



## Standard Treatment Workflow (STW) for the Management of ATRIAL FIBRILLATION ICD-10-I48.91

**WHEN TO SUSPECT ?**

**SYMPTOMS**

- Rapid rate palpitations with or without
  - General fatigue or weakness or exhaustion
  - Dizziness, near syncope or syncope
  - Shortness of breath
  - Chest pain
- More marked on exertion

**LOOK FOR PRECIPITATING FACTORS:**

- Post (cardiac) surgery
- Alcoholism or binge drinking
- Myo-pericarditis or ACS
- Pneumonitis or pulmonary embolism
- Sepsis, hyperthyroidism

**CATEGORIZE AF**

- Paroxysmal AF: Episodes of AF for less than 7 days
- Persistent AF: AF lasting from 7 days to 1 year
- Long standing persistent AF: AF lasting for >1 year
- Permanent AF: AF with heart rate control as only option

**SIGNS**

- Irregularly irregular pulse
- Variable heart sound

**LOOK FOR RISK FACTORS**

- Prior valvular heart disease or CHF or MI
- Prior TIA or stroke or embolic episode
- Hypertension, DM, COPD, CKD, Obesity

**MANAGEMENT PRINCIPLES:**

- Categorize AF
- Look for immediate intervention indicators
- Assess stroke risk & need for anti-coagulation
- Assess bleeding risk
- Need for rate control
- Consideration for rhythm control

**LOOK FOR IMMEDIATE INTERVENTION INDICATORS:**

- Systolic BP 90 mmHg, HR > 150 or <50/min
- Ongoing Angina
- CHF or TIA or stroke
- Major bleed on Oral Anti-coagulants

STROKE RISK SCORE		BLEEDING RISK SCORE	
CHA <sub>2</sub> DS <sub>2</sub> -VAS <sub>2</sub>	SCORE	HAS-BLED	SCORE
- Congestive heart failure/LV dysfunction	1	- Hypertension i.e. uncontrolled BP	1
- Hypertension	1	- Abnormal renal/ liver function	1 or 2
- Aged > 75 years	2	- Stroke	2
- Diabetes mellitus	1	- Bleeding tendency or predisposition	1
- Stroke/TIA/ TE	2	- Labile INR	1
- Vascular disease [prior MI, PAD or aortic plaque]	1	- Age (e.g. >65)	1
- Aged 65-74 years	1	- Drugs (e.g. concomitant aspirin or NSAIDs or alcohol)	1
- Sex category [i.e. female gender]	1		
Maximum Score	9		9

OAC if score >1 in men and >2 in women      Bleeding Risk High in score >3

**CHOICE OF ANTI-COAGULATION:**

- Vitamin K antagonist
  - Aim for INR 2-3
  - Assess risk of bleeding
  - Take measures to reduce/ modify risk of bleeding
  - Dietary modification & regular monitoring

**MEASURES TO REDUCE HIGH BLEEDING RISK:**

- Control SBP to less than 140 mmHg
- Avoid dietary indiscretions
- Avoid concomitant aspirin, anti platelets, NSAIDs
- Avoid alcohol
- Correct anemia

HEART RATE CONTROL			
In all patients except hemodynamic instability	Beta blocker or calcium blocker or combination	BB ± digoxin in HF	Rate aim to be less than 110/ min

CONVERSION TO NSR			
Hemodynamic instability	Uncontrolled symptoms despite HR control	Unacceptable rate control drug side effects	Patients' preference

**MANAGEMENT**

**AT PHC/ CHC:**

- Detailed clinical evaluation
- Basic investigations
- Careful ECG evaluation
- Start OAC if indicated (based on Stroke risk)
- Start Metoprolol if HR >110/ min & no evidence of CHF
- Refer if indicators for early intervention

**AT DISTRICT HOSPITAL:**

- Admit if indicators of early interventions
- Immediate cardioversion after heparinization, if hemodynamic instability
- Manage precipitating factors if any
- Assess stroke, bleeding risk & coagulation parameters
- Detailed echocardiogram
- Start OAC, maintain INR around 2-3
- Control HR by single drug or combination of BB & Ca Blocker

Refer HR uncontrolled or CHF or angina

**AT TERTIARY CENTRE:**

- Re-assess clinical status, adequacy of AC
- Consider need of NOAC
- Optimise management of underlying cardiac disease
- Stress life style and AF risk factor modification
- Assess need for rhythm control and discuss pros & cons
- Consider RFA in select patient

**INVESTIGATIONS**

**BASIC INVESTIGATIONS:**

- Hemograms
- Blood sugar, Creatinine
- Electrolytes
- 12 lead ECG

**DESIRABLE INVESTIGATIONS:**

- Plain X-ray chest
- Thyroid evaluation
- Liver function test
- Troponins
- Prothrombin time, INR (Coagulation profile)
- Echocardiography

**OPTIONAL INVESTIGATIONS:**

- Prolonged ECG monitoring
- Trans-oesophageal echocardiography
- Exercise Stress Test
- CT scan
- MRI
- EP study
- Coronary angiography

**WHAT TO LOOK FOR IN ECG ?**

- Ventricular rate
- Chamber enlargement
- Pre-excitation
- Prior MI
- Bundle branch block
- QT interval

**RHYTHM CONTROL**



Pharmacological Cardioversion

- CHF, CAD, Abnormal LVH: Amiodarone
- Normal Heart: Flecainide, Ibutilide, Propafenone
- Pill in pocket (Flecainide OR Propafenone)

Long Term Rhythm Control

- CHF: Amiodarone
- Normal Heart: Flecainide, Propafenone, Sotalol
- CAD, LVH: Amiodarone, Sotalol

**MANAGEMENT ALGORITHM**



**Anti-coagulants in all Except**

- Reversible
- Score <1 (men); <2 (women)

**KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES**

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal ([stwjcmr.org.in](http://stwjcmr.org.in)) for more information.

© Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.